Celgene’s Otezla OK’d in plaque psoriasis

The FDA on 23 September gave Celgene the go-ahead to market Otezla (apremilast), a selective inhibitor of phosphodiesterase 4 (PDE4), to treat moderate to severe plaque psoriasis for whom phototherapy or systemic therapy is appropriate.